By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

We are excited to welcome back Kobe Biomedical Innovation Cluster (KBIC) as a Title Sponsor of RESI JPM 2027! Continuing our partnership, KBIC will once again bring together promising life science innovators from across Asia, connecting emerging technologies with the global investment and partnering community.
As part of this collaboration, Japan – Asia Life Science Showcase will take place on January 11, 2027, from 1:00 – 3:00 PM at the San Francisco Marriott Marquis, during RESI JPM 2027.
This special two-hour showcase will feature eight innovative life science companies advancing technologies across oncology, regenerative medicine, cell therapy, infectious diseases, and medical technologies. From pioneering tooth regeneration therapies and next-generation cancer immunotherapies to engineered bacteriophages and brain-computer interfaces, these companies highlight the diversity and growing potential of Asia’s life science innovation ecosystem.
For investors, pharmaceutical companies, and business development professionals, this session offers an opportunity to discover emerging technologies and explore potential investment, licensing, and strategic partnership opportunities.
Meet the 8 Featured Companies
Toregem BioPharma Co., Ltd.
Toregem BioPharma is developing a groundbreaking approach to tooth regeneration through its lead antibody candidate, TRG035, targeting USAG-1 to stimulate natural tooth development. Following Phase I clinical development, the company is advancing its program toward treating congenital tooth agenesis, with the potential to transform dental and regenerative medicine.
Crafton Biotechnology Co., Ltd.
Crafton Biotechnology is leveraging its proprietary PureCap® mRNA platform to develop next-generation therapeutics that enable sustained antibody production within the body. By potentially reducing treatment frequency and improving patient convenience, the company aims to address unmet medical needs in autoimmune and other chronic diseases.
A-SEEDS Co., Ltd.
A-SEEDS is advancing innovative CAR-T cell therapies targeting acute myeloid leukemia and solid tumors. Utilizing its proprietary non-viral piggyBac transposon platform, the company is developing durable, tumor-selective cell therapies designed to overcome key limitations of conventional CAR-T treatments.
Arrowsmith Inc.
Arrowsmith is harnessing synthetic biology to develop engineered bacteriophage therapies targeting antimicrobial-resistant infections. Its precision-based approach selectively eliminates harmful bacteria, including Pseudomonas aeruginosa, offering a potential alternative to conventional antibiotics in addressing the growing global antimicrobial resistance crisis.
LIFESCAPES Inc.
LIFESCAPES is developing non-invasive brain-computer interface (BCI) technology designed to restore hand movement in patients with severe paralysis resulting from stroke or spinal cord injury. By integrating brain signal monitoring, advanced software, and robotic assistance, its technology aims to improve rehabilitation outcomes and patients’ quality of life.
Periotherapia Co., Ltd.
Periotherapia is developing innovative antibody therapies targeting pathological periostin, a key component of the tumor microenvironment associated with treatment resistance. By disrupting protective barriers surrounding tumors, its approach aims to enhance drug penetration and improve the effectiveness of existing cancer therapies.
CynosBio, Inc.
CynosBio specializes in autologous cell therapies addressing unmet needs in ophthalmology and orthopedics. Its portfolio includes Sakracy, an approved regenerative therapy for severe ocular surface disorders in Japan, alongside a Phase III knee cartilage regeneration program, positioning the company for potential international clinical development and commercialization.
Mustbio Co., Ltd.
Mustbio is advancing next-generation cancer immunotherapies through its proprietary multi-specific antibody platform. Its tri-specific fusion protein targets PD-1, VEGF, and IL-21 pathways to enhance anti-tumor immune responses and potentially overcome resistance to existing immunotherapies, particularly in patients with refractory or relapsed cancers.
Join Us at Japan – Asia Life Science Showcase during RESI JPM 2027!
Date: Monday, January 11, 2027
Time: 1:00 – 3:00 PM (PST)
Location: San Francisco Marriott Marquis
| RSVP for Japan – Asia Life Science Showcase |
Whether you are an investor seeking promising early-stage opportunities, a pharmaceutical company exploring innovative technologies, or a business development professional looking to expand your network, Japan – Asia Life Science Showcase offers an opportunity to connect with emerging life science innovators from across Asia.
Join us at RESI JPM 2027 to discover breakthrough technologies, meet innovative founders, and explore new opportunities for global collaboration!
| Register for RESI JPM 2027 |

